Amicus Therapeutics, Inc.
FOLD
Rang in aandelen
#3706
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Aandeelprijs
$14.49
Laatst gesynchroniseerd: 2026-04-27
Marktkapitalisatie
$4.55B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
71.07%
Land
US
Handel Amicus Therapeutics, Inc. (FOLD)
Categorie
Healthcare
Omzet van Amicus Therapeutics, Inc. (FOLD)
Omzet in Dec 2025 TTM: $634.21M
Volgens de laatste financiële rapporten van Amicus Therapeutics, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $634.21M. In 2023 behaalde het bedrijf een omzet van $399.36M een stijging ten opzichte van de omzet in het jaar 2022, die $329.23M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Amicus Therapeutics, Inc. van 2003 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $634.21M | 20.05% |
| 2024 | $528.30M | 32.29% |
| 2023 | $399.36M | 21.30% |
| 2022 | $329.23M | 7.76% |
| 2021 | $305.51M | 17.11% |
| 2020 | $260.89M | 43.16% |
| 2019 | $182.24M | 99.72% |
| 2018 | $91.25M | 147.08% |
| 2017 | $36.93M | 644.86% |
| 2016 | $4.96M | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $1.22M | 237.19% |
| 2013 | $363.00K | -98.03% |
| 2012 | $18.41M | -14.10% |
| 2011 | $21.43M | 2,224.73% |
| 2010 | $922.00K | -98.57% |
| 2009 | $64.36M | 330.00% |
| 2008 | $14.97M | 738.96% |
| 2007 | $1.78M | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 1,890.56% |
US
|
|
| $2.23B | 251.30% |
US
|
|
| $15.74B | 2,382.51% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 849.42% |
NL
|
